risedronate
英
美
网络 利塞膦酸盐; 利塞膦酸钠; 利塞膦酸; 利塞磷酸; 和利塞膦酸盐
双语例句
- Adverse events did not differ significantly between the risedronate and placebo groups, the investigators say.
研究人员说，治疗组和安慰剂组的不良反应发生率无显著差异。 - Effects of risedronate sodium on serum BGP and urine NTX/ Cr in patients with postmenopausal osteoporosis
利塞膦酸钠对绝经后骨质疏松症患者血BGP及尿NTX/Cr的影响 - Analysis on influencing factor of effect for treating postmenopausal osteoporosis with risedronate sodium capsules
利塞膦酸钠胶囊治疗绝经后骨质疏松症疗效的影响因素分析 - In women on an aromatase inhibitor and risedronate, spine BMD fell by2.4% and remained stable at the hip.
利塞膦酸组中，服用芳香化酶抑制剂的妇女脊柱骨密度下降2.4%，全髋关节密度保持不变。 - Objective To study the effects of risedronate sodium on bone mineral density ( BMD) and bone biochemical marker in primary osteoporosis.
目的评价利塞膦酸钠对原发性骨质疏松症骨密度和骨转换指标的影响。 - Risedronate sodium in prevention and treatment for postmenopausal osteoporosis Comparison of traditional Chinese medicine ( Qiang-gu capsule) and Risedronate sodium in management of postmenopausal osteoporosis
利塞膦酸钠在防治绝经后骨质疏松症中的作用强骨胶囊与利塞膦酸钠治疗绝经后骨质疏松症的对比研究 - The skeletal effects of risedronate combined with prostaglandin E_2 in ovariectomized rats
利塞膦酸钠和前列腺素E2联合用药对去卵巢大鼠骨骼的影响 - Measurements of Osteocalcin and Cross-linked N-telopeptide of Type 1 Collagen in Postmenopausal Osteoporosis and the Application of Risedronate in Its Prevention and Treatment
绝经后骨质疏松症骨钙素和1型胶原交联氨基端肽测定意义以及利塞膦酸钠防治研究 - After 12 months overall effective rate in risedronate sodium group and control group were 93.10% and 80.77%, respectively.
12个月骨密度综合疗效为：治疗12个月试验组和对照组总有效率分别为93·10%和80·77%。 - This article reviews risedronate sodium in its pharmaco-mechanism, pharmacokinetics, clinical application and adverse reaction.
本文综述了利塞膦酸钠的药理机制、药代动力学、临床应用及不良反应。 - Conclusions Risedronate was a safe and effective medicine to treat PMOP; It can decrease serum bone specific alkaline phosphatase and urinary hydroxyproline bone turnover and increased BMD in postmenopausal osteoporotic women.
结论利塞膦酸钠可提高预绝经后骨质疏松妇女骨密度，降低血清骨特异性碱性磷酸酶及尿羟脯氨酸。 - Risedronate may promote the bone formation.
利塞膦酸钠可促进人成骨样细胞MG63碱性磷酸酶的活性，可能对骨形成具有促进作用。 - Objective To investigate the effects of risedronate intervention on bone mineral density ( BMD), serum bone specific alkaline phosphatase and urinary hydroxyproline in postmenopausal osteoporotic women.
目的用利塞膦酸钠治疗绝经后骨质疏松妇女6个月，观察其对骨密度（BMD）、血清骨特异性碱性磷酸酶、尿羟脯氨酸的影响。 - A Synthetic Method of the Bone Resorption Inhibitor Amino bisphosphonates and Their Sodium Salts An intermediate of bone resorption inhibitor risedronate sodium, 3 pyridine acetic acid hydrochloride, was synthesized from ethyl nicotinate via reduction, chlorination, cyanation and hydrolysis.
骨吸收抑制剂氨基二膦酸类化合物及其钠盐的合成以烟酸乙酯为原料，经还原、氯代、氰化、水解等反应合成了骨吸收抑制剂利塞膦酸钠中间体3-吡啶乙酸盐酸盐。 - Risedronate sodium, a third-generation bisphosphonate with pyridyl, is the earliest protein inhibitor of bone absorption on market and its effect was stronger than earlier the first and second-generation products.
利塞膦酸钠为第三代双膦酸盐类抗骨质疏松药物中上市较早，疗效明显的强于一、二代产品。